“This is the bottom line. We couldn't find any subset that didn't benefit from trastuzumab,” he said, acknowledging the subsets were small.
In patients deemed negative by both IHC and FISH, the relative risk of recurrence was 0.34.
Noting that the parameters of HER2 positivity originated in the metastatic setting, Dr. Paik and his associates concluded that the “current definition of HER2 overexpression/gene amplification based on data from advanced disease may need to be modified for the adjuvant setting.”